Apo-A1

Apo-A1

Apo-A1 Informations sur la molécule

Molecule Name
Apolipoprotein A-I
Alias de la molécule
Apolipoprotein A-I,APOA1,MGC117399
Drug Development Progress
Nombre de médicaments cliniques3
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
Epididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
Contexte de la molécule
ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
ZerlasiranSLN-360Phase 2 ClinicalSilence Therapeutics Plc
Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders
Details
Fx-5AFx-5APhase 1 ClinicalKinemed Inc
Cardiovascular Diseases
Details
Recombinant NV-A01 adenovirusPhase 1 ClinicalNanjing Nuowei Biotechnology Co Ltd
Glioblastoma; Solid tumours
Details